India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to get U.S.-based immunotherapy and targeted oncology institution Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) for an upfront currency outgo of $4.10/share.

In December, the FDA approved Checkpoint Therapeutics’ Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous compartment carcinoma (cSCC) oregon locally precocious cSCC who are not candidates for curative surgery oregon curative radiation.

Unloxcyt is the archetypal and lone programmed decease ligand-1 (PD-L1) blocking antibody to person FDA selling support for this indication.

The recommended commercialized dosage of Unloxcyt is 1,200 mg administered arsenic an intravenous infusion implicit 60 minutes each 3 weeks.

Also Read: nVent Electric Strikes $975 Million Deal To Power Up Infrastructure: Details

Stockholders volition person a non-transferable contingent worth close (CVR) of up to an additional $0.70/share successful currency if cosibelimab is approved earlier definite deadlines successful the European Union pursuant to the centralized support process oregon in Germany, France, Italy, Spain or the United Kingdom.

The upfront currency outgo of $4.10 per stock of communal banal represents a premium of astir 66.0% to Checkpoint’s closing stock terms on March 7, 2025, the past trading time earlier the announcement.

In transportation with the transaction, Fortress Biotech, Inc. (NASDAQ:FBIO), Checkpoint’s controlling stockholder, Checkpoint and Sun Pharma person entered into a royalty agreement, nether which pursuing the closing of the transaction, Fortress would beryllium entitled to person royalty payments based connected aboriginal income of cosibelimab during a specified term, successful lieu of royalty rights that were granted to Fortress successful transportation with its founding of Checkpoint.

The transaction is expected to beryllium completed successful the 2nd calendar 4th of 2025.

For the nine-month play ending September 2024, Checkpoint reported $0.04 million in gross and a nett nonaccomplishment of $27.3 million.

Price Action: CKPT banal is up 64.2% astatine $4.055 astatine the past cheque Monday.

Read Next:

• USA Targets DeepSeek, Weighs Restrictions On China’s AI Firm That Shook Nvidia’s Market Value By $600 Billion

Photo via Shutterstock.

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.

Get the latest banal investigation from Benzinga?

This nonfiction India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details primitively appeared connected Benzinga.com

© 2025 Benzinga.com. Benzinga does not supply concern advice. All rights reserved.